Morgan Stanley
TRVI icon

Morgan Stanley’s Trevi Therapeutics TRVI Stock Holding History

Morgan Stanley’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Buy
800,465
+69,210
+9% +$1.01M ﹤0.01% 3366
2026
Q1 		$8.72M Sell
731,255
-319,041
-30% -$3.57M ﹤0.01% 3676
2025
Q4 		$13.1M Sell
1,050,296
-3,251,430
-76% -$37.6M ﹤0.01% 3353
2025
Q3 		$39.4M Buy
4,301,726
+3,277,715
+320% +$24.6M ﹤0.01% 2224
2025
Q2 		$5.6M Buy
1,024,011
+529,444
+107% +$3.29M ﹤0.01% 3968
2025
Q1 		$3.11M Buy
494,567
+303,698
+159% +$1.45M ﹤0.01% 4301
2024
Q4 		$786K Sell
190,869
-7,611
-4% -$24.4K ﹤0.01% 5212
2024
Q3 		$663K Buy
198,480
+109,499
+123% +$325K ﹤0.01% 5268
2024
Q2 		$265K Buy
88,981
+20,754
+30% +$57.7K ﹤0.01% 5557
2024
Q1 		$235K Sell
68,227
-80,776
-54% -$180K ﹤0.01% 5677
2023
Q4 		$200K Buy
149,003
+114,289
+329% +$173K ﹤0.01% 5704
2023
Q3 		$75.7K Sell
34,714
-3,077
-8% -$6.95K ﹤0.01% 6001
2023
Q2 		$90.3K Buy
37,791
+37,407
+9,741% +$94.3K ﹤0.01% 5997
2023
Q1 		$710 Sell
384
-55
-13% -$124 ﹤0.01% 7390
2022
Q4 		$848 Sell
439
-427,966
-100% -$844K ﹤0.01% 7488
2022
Q3 		$660K Buy
+428,405
New +$1.4M ﹤0.01% 5120
2022
Q2 		– Sell
-589
Closed -$1K – 7974
2022
Q1 		$1K Buy
+589
New +$610 ﹤0.01% 7873
2021
Q2 		– Sell
-1,000
Closed -$3K – 7804
2021
Q1 		$3K Buy
+1,000
New +$2.93K ﹤0.01% 7222
2019
Q4 		– Sell
-114
Closed -$1K – 6763
2019
Q3 		$1K Sell
114
-5,545
-98% -$30.1K ﹤0.01% 6578
2019
Q2 		$42K Buy
+5,659
New +$48.7K ﹤0.01% 5681

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Morgan Stanley's TRVI Position: Q2 2026 in Review

Morgan Stanley increased its Trevi Therapeutics (TRVI) stake by 9.5% in Q2 2026, buying an estimated $1.01M and bringing the position to 800,465 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3366.

Morgan Stanley first reported a position in TRVI in Q2 2019 and has held it in 20 quarters since. The position peaked at $39.4M in Q3 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Morgan Stanley held 800,465 shares of Trevi Therapeutics worth $14.9M as of Q2 2026.
  • Morgan Stanley bought 69,210 Trevi Therapeutics shares in Q2 2026, an estimated $1.01M.
  • Trevi Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3366 holding.
  • Morgan Stanley first reported a position in Trevi Therapeutics in Q2 2019 and has held it in 20 quarters since.
  • Morgan Stanley's Trevi Therapeutics position peaked at $39.4M in Q3 2025.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.